Recurrent Breast Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionTreatment